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HYPERLIP IDEMIA
Low Density Lipoprotein Apheresis Improves Regional Myocardial 
Perfusion in Patients With Hypercholesterolemia and Extensive 
Coronary Artery Disease
The LDL-Apheresis Atherosclerosis Regression Study (LAARS)
WIM R. M. AENGEVAEREN, MD, ABRAHAM A. KROON, MD,
ANTON F. H. STALENHOEF, MD, PhD, GERARD J. H. UIJEN, PhD,
ments were assessed in 43 regions in the LDL apheresis group and 
35 regions in the medication group. In the LDL apheresis group,
TJEERD v a n  d e r  WERF, MD, PhD, FACC
Nijmegen, The Netherlands
Objectives. In a randomized study we evaluated the effect of 
biweekly low density lipoprotein (LDL) apheresis plus simvastatin 
versus medication alone on regional myocardial perfusion.
Background. In patients with severe hypercholesterolemia, diet 
and lipid-lowering drugs are often insufficient to achieve optimal 
LDL cholesterol values. Low density lipoprotein apheresis is a 
very effective lipid-lowering therapy. Assessment of regional myo­
cardial perfusion enables evaluation of the functional state of the 
coronary circulation.
Methods. We studied 42 patients with severe hypercholesterol­
emia and extensive coronary artery disease who were randomized 
to diet and simvastatin with or without biweekly LDL apheresis. 
Regional myocardial perfusion was assessed by digital subtraction 
angiography with videodensitometric calculation of hyperemic 
mean transit time (HMTT) of contrast medium at baseline and 
after 2 years of therapy.
Results. Low density lipoprotein cholesterol decreased by 63% 
(to 3.0 mmol/liter) in the LDL apheresis group and by 47% (to 
4,1 mmol/liter) in the medication group. Paired HMTT measure­
regional HMTT decreased over 2 years from 3.35 ±  1.18 (mean ± 
SD) to 2.87 ±  0.82 s (-“14%, p = 0.001), whereas no change in the 
medication group was observed: 2.95 ± 1.06 to 2.96 ± 0.90 s (p = 
NS). In the patient-based comparison, the mean change in HMTT 
was -0 .45 s (-14%, p =  0.01) in the LDL apheresis group and 
-0.05 s (“ 2%, p = NS) in the medication group, respectively, 
Only exercise-induced ischemia improved in the LDL apheresis 
group.
Conclusions. Biweekly LDL apheresis plus simvastatin decreased 
time-averaged LDL cholesterol levels by an additional 31% (1.1 
mmolfliter) compared with medication alone. After 2 years of ther­
apy, regional myocardial perfusion improved in the LDL apheresis 
group and remained unchanged in the medication group. Thus, 
aggressive reduction of LDL cholesterol has a favorable effect on 
regional myocardial perfusion and alleviates ischemia.
(J Am Coll Cardiol 1996;28:1696-704) 
©1996 by the American College of Cardiology
Low density lipoprotein (LDL) cholesterol levels often remain 
elevated in patients with familial hypercholesterolemia (FH) 
despite diet and cholesterol-lowering drugs. High LDL choles­
terol levels are strongly associated with premature develop­
ment of coronary artery disease, especially in men with an 
inherent risk of coronary death (1), Low density lipoprotein
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apheresis is considered a valuable therapeutic option for 
patients with homozygous FH and for patients with coronary 
artery disease and hypercholesterolemia refractory to diet and 
drugs (2-4). It has been shown in a number of nonrandomized 
studies (2,5-8) that plasma exchange or LDL apheresis led to 
regression or slowing of progression of coronary atheroscle­
rotic lesions and resolution of xanthomas. The use of plasma 
exchange was also associated with increased survival among 
patients with homozygous FH compared with their untreated 
homozygous siblings (9). In one recently published randomized 
trial in patients with FH (10), biweekly LDL apheresis versus 
drug therapy for 2 years showed no difference in coronary 
anatomy as measured by quantitative coronary angiography 
(QCA) (10). In the LDL-Apheresis Atherosclerosis Regres­
sion Study (LAARS) (11), there was also no difference in 
quantitatively assessed coronary anatomy, but patients under­
going LDL apheresis had a significant improvement in exercise 
variables versus patients on drug therapy alone. Questions
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Abbreviations and Acronyms
DSA =  digital subtraction angiography
FH =  familial hypercholesterolemia
HMTT =  hyperemic mean transit time (of contrast
medium)
' LAARS =  LDL-Apheresis Atherosclerosis Regression Study
LA D =  left anterior descending coronaiy artery
LCx =  left circumflex coronary artery
LDL =  low density lipoprotein
QCA =  quantitative coronaiy angiography
RCA =  right coronary artery
1 R O I =  region of interest
remain about 1) the cause of this functional improvement, 2) 
the  methods for evaluating the potential benefits in aggressive 
lipid-lowering therapy, and 3) the impact on patient care. 
Traditionally, clinical end points, such as improved survival 
an d  reduction of major cardiac events, are the best proof of 
effect in lipid-lowering trials but require numerous patients 
over a long period of time (12,13). Quantitative coronary 
angiography is the present reference standard for evaluating 
lipid-lowering therapy in coronary artery disease (14-16). 
However, application of QCA has several limitations, such as 
th e  diffuse character of coronaiy artery disease, complexity of 
stenosis geometry, foreshortening in nonorthogonal views, 
insufficient contrast staining and limited resolution of the 
radiographic chain (16-18). Moreover, there seems to be a 
dissociation between the results of angiographic studies and 
clinical outcome. Lipid-lowering therapy reduces the incidence 
o f  cardiovascular events to a greater extent than the propor­
tionate changes in plaque dimensions suggest (15,19). Reduc­
tion of hypercholesterolemia retards the progression of coro­
nary atherosclerosis by depleting the lipid core of the plaque 
and  deminishing the inflammatory process; not the change in 
angiographic lumen size but the process of plaque stabilization 
appears to decrease the risk of disruption with fewer clinical 
events (20). The endothelium plays a major role in regulating 
the  vascular smooth muscle tone. Endothelial dysfunction can 
result in an impaired blood flow of the large and small 
coronary arteries (21-25). Dysfunction of endothelium- 
mediated vasomotion is associated with atherosclerosis, hyper­
cholesterolemia and smoking in adults and is already present 
in the systemic arteries of children with heterozygous FH 
(21-26). Lipid-lowering therapy improves the endothelium- 
mediated vasomotion after relatively short periods of time 
(27-29). The functional improvement of the coronary circula­
tion precedes structural improvement (30). The cumulative 
effects of all anatomic and functional abnormalities of the 
epicardial coronary arteries in combination with possible dys­
function of conduit and resistance vessels are responsible for 
the  ultimate effect of atherosclerosis on myocardial perfusion. 
In  this setting, it should be emphasized that minor changes in 
lumen diameter of the coronaiy arteries have a major effect on 
vascular resistance, according to Poisseuille’s law.
To evaluate the functional state of the coronaiy circulation
after aggressive lipid-lowering therapy with LDL apheresis, we 
assessed regional myocardial perfusion by means of digital 
subtraction angiography (DSA) followed by videodensitomet- 
ric calculation of the hyperemic mean transit time (HMTT) of 
contrast medium in the LAARS trial.
Methods
The purpose of the study was to compare the effects of 
aggressive lipid-lowering treatment by LDL apheresis versus 
conventional treatment on the anatomy and functional state of 
the coronary tree. The trial design, patient characteristics, 
methodology of lipid measurements, QCA and exercise testing 
have been described previously (11). Briefly, consenting pa­
tients with extensive coronary artery disease and hypercholes­
terolemia were randomized to diet and 40 mg of simvastatin 
once daily with or without biweekly LDL apheresis. The 
inclusion criteria were 1) male patients between 18 and 70 
years old; 2) extensive coronary atherosclerosis demonstrated 
by cardiac catheterization; 3) total serum cholesterol ^8.0 
mmol/liter or LDL cholesterol >5.8 mmol/liter and serum 
triglycerides ^5.0 mmol/liter during a standard lipid-lowering 
diet. The ethics committee of the University Hospital of 
Nijmegen approved the study, The study cohort included 42 
male patients with a mean (±SD) age of 52.0 ± 9.2 years 
(range 29 to 69). The elevated lipid levels were due to 
heterozygous FH in 32 patients (76%), 16 in each group, In the 
remaining 10 patients, the diagnosis was primary hypercholes­
terolemia in 8 (19%) and familial combined hypercholesterol­
emia in 2 (5%). In the LDL apheresis group, 17 patients had 
three-vessel disease, and 4 had two-vessel disease, whereas in 
the medication group 19 patients had three-vessel disease, and
2 had two-vessel disease (a vessel was considered diseased 
when there was >50% diameter stenosis in a major branch). 
Before entry into the study, all patients had a 2-month run-in 
period. Antianginal medication was continued, but lipid- 
lowering medication was stopped. If total cholesterol remained 
elevated above the lower limit for inclusion into the study, 
cardiac catheterization and exercise testing were carried out. 
After cardiac catheterization, patients were randomized in a 
stratified way, which took into account the total cholesterol 
and lipoprotein(a) levels, age and history of coronaiy bypass 
surgery. Antianginal medication was continued at the same 
doses during the trial. If adaptation in medication was neces­
sary during the study, the original prescription, if possible, was 
restored before the follow-up cardiac catheterization. The 
follow-up cardiac catheterization was performed 1 month after 
the last LDL apheresis. Low density lipoprotein apheresis was 
performed with an automated system MA-01 (Kanegafuchi 
Chemical Industry Co. Ltd, Osaka, Japan) with two small-sized 
dextran sulfate cellulose columns that were used and regener­
ated alternately in one procedure, permitting continuous 
apheresis (11). Before the start of the LDL apheresis, all 
patients received 10,000 U of heparin. A volume of 5,000 ml 
(~1.5 plasma volume) was treated per session.
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Figure 1. Example of the positioning 
of the ROIs in one of the subtracted 
images of the coronary arteries early 
after contrast injection. Left panel, 
LAD in the 60° left anterior oblique 
projection. Right panel, RCA in the 
30° right anterior oblique projection. 
B = background ROI; Cl,2 = ROIs 
1 and 2 in perfusion area of LCx; 
LI ,2 = ROIs 1 and 2 in perfusion 
area of LAD; P = ROI at catheter 
tip; Rl,2 = ROIs 1 and 2 in perfu­
sion area of RCA.
Assessment of regional myocardial perfusion, We used the 
method of DSA, followed by videodensitometry and calcula­
tion of the HMTT of contrast to compare the maximal regional 
myocardial perfusion in the areas of the left anterior descend­
ing coronaiy artery (LAD), left circumflex coronaiy arteiy 
(LCx) and right coronary arteiy (RCA) at baseline and at 
follow-up. This method has been developed in our laboratory 
and has been validated in model studies, animal experiments 
and in humans (31-34), Before cardiac catheterization, pa­
tients were trained to hold their breath with use of a nose 
clamp at maximal inspiration for 15 to 20 s. After completion 
of angiography of the LAD, the left Judkins catheter with a 7F 
tip (Cordis) was left in place for the DSA protocol, in which a 
60° left anterior oblique projection was used. After angiogra­
phy of the RCA, the protocol was repeated in the 30° right 
anterior oblique projection. Meticulous care was taken to 
repeat the follow-up DSA under exactly the same circum­
stances, with the same medication.
At the start of the procedure, a 5F stimulation catheter was 
positioned in the right atrium. During DSA, the heart was 
triggered in synchrony with the radiographic pulses, slightly 
above its inherent rate, to provide a strictly regular heart 
rhythm. Iohexol-350 (Nycomed AS, Oslo, Norway), a nonionic 
low osmolar contrast agent was used. For all studies, 6 ml of 
contrast medium was injected, using a power injector at a 
speed of 4 ml/s. Twenty-five seconds after administration of 8 
to 12 mg of papaverine (depending on the size of the vascular 
bed), the patient was instructed to hold his breath, and image 
acquisition was started 5 s later followed by contrast injection. 
One image/heart cycle was obtained just before the onset of 
the QRS complex. Image acquisition was performed on a Bicor 
radiograph system connected to a Digitron-3 computer for 
digital subtraction angiography (Siemens AG, Erlangen, Ger­
many). Images were generated with the automatic brightness 
control switched off after the fourth image in every study to 
enable density calculation. Subsequently, the images were 
digitized in a 512 X 512 matrix with 1,024 density levels. The 
image quality was checked immediately after image acquisi­
tion) and if necessary the imaging protocol was repeated a 
maximum of three times.
Image and data processing were performed off-line using a 
Sun SPARC station 10 (Sun Microsystems, Inc.) with pro­
grammed Khoros software. Circular regions of interest (ROIs) 
of 200 to 600 pixels were constructed over the tip of the 
coronary catheter to record the contrast injection and over the 
myocardium supplied by the respective vessels (Fig. 1). The 
ROIs were chosen at the myocardial level on predefined 
localizations, carefully avoiding overlap with major side 
branches and veins. Close to the myocardial ROI, a back­
ground ROI was chosen to analyze changes in background 
density (Fig. 1). Time-density curves were generated by sam­
pling the averaged pixel density within a ROI in consecutive 
images and, subsequently, these curves were fitted with a 
gamma-variate function. In case of deviating background den­
sity, the fitted curves of the myocardial ROIs were corrected 
with the corresponding background ROI. The HMTT is the 
difference in the mean transit time of the contrast medium at 
the myocardial ROI and at the injection site ROI (ROI at 
catheter tip). Because of the pressure dependency of flow 
during maximal hyperemia, HMTTs were corrected for a 
normalized mean aortic blood pressure of 100 mm Hg for 
comparison between the two studies. This correction was 
performed by multiplying the mean transit time in seconds by 
the ratio Pa/100, where Pa is the actual mean blood pressure 
during image acquisition. If a pressure curve showed a pressure 
drop or wedging during hyperemia, indicating that the catheter 
influenced maximal flow, the study was excluded from further 
analysis. Myocardial areas that were subjected to a Q wave 
myocardial infarction or occlusion of the proximal vessel were 
excluded from analysis.
For final analysis, paired time-density curves of sufficient 
quality without artifacts were selected by a cardiologist 
(W.R.M.A.) who had no knowledge of treatment allocation. 
Figure 2 shows an example of paired time-density curves of an 
ROI. The final data base was composed, and subsequent 
HMTTs were calculated and corrected for blood pressure, as 
stated before. Regional myocardial perfusion was assessed by 
averaging the comparative HMTTs (one to two ROIs) in the 
area supplied by the LAD, LCx and RCA to one value/ 
perfusion area per session. Perfusion areas supplied by bypass
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Figure 2. Example of paired time-density curves of ROI at 
baseline (upper panel) and at follow-up (lower panel). The 
HMTT values are calculated from these curves, where the 
onset of time is derived from the time-density curve of 
the respective ROI at the injection site (not shown).
grafts were also imaged by the DSA protocol, carefully avoid­
ing evaluation of perfusion areas with competitive flow 
through native coronary artery and bypass graft. The ROIs of 
perfusion areas supplied by bypass grafts were classified as part 
o f  the original coronary artery region. Analysis of the effect of 
b o th  lipid-lowering treatments on myocardial perfusion was 
calculated from HMTT values derived from individual ROIs 
from  a regional“ and patient-based assessment of HMTT. The 
patient-based evaluation was performed by averaging the 
regional HMTT values to one value per patient as a global 
estimate of myocardial perfusion. Analysis of the patient-based 
H M T T  values was performed both with and without correction 
fo r change in hematocrit. For this correction the HMTT values 
a t  follow-up were subtracted by the percent change in hemat­
ocrit, assuming a linear relation between hematocrit and blood 
viscosity in this narrow range of actual hematocrit values (35).
Statistical analysis. Comparisons of prespecified continu­
ous variables within groups were made by two-sided paired t 
tests and between-group analysis by unpaired t tests for 
normally distributed data. For categoric comparison, a chi- 
square test was performed when appropriate. Correlations 
were tested with the Pearson correlation coefficient. For all 
hypothesis tests, a two-sided p value <0.05 was considered 
significant. Results are expressed as mean value ± SD, unless 
otherwise indicated.
Results
Forty-two male patients were randomized into two groups 
of 21 patients in our center. The results in both groups for lipid
metabolism, QCA, exercise testing and clinical events have 
been described elsewhere (11). In short, LDL cholesterol 
decreased in the LDL apheresis group from 7.78 ±  '1.86 
mmol/liter to a time-averaged value of 2.95 ±1.13 mmol/liter 
and from 7.85 ± 2.34 to 4.13 ± 1.58 mmol/liter in the 
medication group. Quantitative coronary angiography showed 
no changes in mean segment diameter and minimal obstruc­
tion diameter within and between the two groups. At exercise 
tests, in the LDL apheresis group versus the medication group, 
time to onset of 1-mm (0.1 mV) ST segment depression was 
prolonged by 39%, and maximal ST segment depression was 
halved, Clinical characteristics and patient-based study data 
are shown in Table 1.
Hyperemic mean transit time. The DSA protocol for cal­
culation of HMTT was performed in all 42 patients. In the 
LDL apheresis group, 19 patients completed the 2 years of 
LDL apheresis; 2 stopped because of progression of angina 
pectoris after 3 and 10 months, respectively. Both patients 
underwent coronaiy artery bypass graft surgery. In the medi­
cation group, one patient underwent bypass surgery after 22 
months of treatment. The HMTT studies of these patients at 
follow-up were considered as end of study measurements. One 
patient in the LDL apheresis group who was admitted to the 
hospital for unstable angina pectoris 12 months after the start 
of the LDL apheresis underwent percutaneous transluminal 
coronary angioplasty of the LAD and the RCA. After coronary 
angioplasty, LDL apheresis was continued, but the two perfu­
sion areas were excluded from assessment of regional myocar­
dial perfusion. In 35 patients (83% [18 in the LDL apheresis 
group, 17 in the medication group]), comparative data from
1700 AENGEVAEREN ET AL.
LDL APHERESIS IMPROVES REGIONAL MYOCARDIAL PERFUSION
JACC Vol. 28, No. 7
Decembcr 1996:1696-704
Table 1. Clinical Characteristics and Patient-Based Study Data
Pt No./Age (yr) Group
Prestudy
Event
LDL Choi (mmol/liter) 
Base During
AMSD
(mm)
AMOD
(mm)
AST Time
(s)
AHMTT
(s)
1/29 L / 12,09 5,67 0.39 Ü.20 -420 0.17
2/59 M I/C 7.01 3.74 0.14 0.15 -0.09
3/67 M A/C 6.62 3.90 0.11 0.05 0 0.97
4/59 M 1/ 7.05 4.26 0.06 0.04 1.46
5/52 M 1/ 5,94 3.58 -0.14 - 0.12 -1.58
6/43 L m i 5.45 2.65 -0,30 -0.24 -30 -0.19
7/69 M I/CP 6.28 3.06 0.11 -0.09
8/67 M i/p 6.5 J 2.69 -0.42 -0.25 2.57
9/46 L I 6.63 3.00 - 0.12 -0.09 -360 -0.62
10/65 L i 6.97 3.76 0.05 0.07 -0.14
11/46 L I/C 7.17 2.76 0.23 0.19
12/46 M A/ 6.11 3.57 -0.08 -0.08 60 -0.75
13/66 L 1/ 6.97 2.14 -0.08 -0.16 -299
14/58 M /C 6.43 3.47 0.07 0.12
15/53 L I/C 6.80 1.98 -0.09 -0.14 -360 -0.38
16/40 M / 9.90 5,32 0.26 0.20 120 0.00
17/58 L I/C 6.71 2.03 0.00 -0.13 -60 -0.51
18/52 L A/C 11.36 5.22 -0.33 -0.06 23 -0.06
19/47 M I/C 12.86 5.62 -0.29 -0,09 -0.41
20/30 L A/C 10.75 3.69 -0.03 -0.06 -330 0.41
21/50 L A/C 7,60 3.12 0.04 0.20
22/45 M NQ/ 9.20 4,95 0.07 0.10 0 - 0.21
23/56 M A/C 11,65 4.93 0.17 0.07 -0.62
24/44 M 1/ 6.59 3.43 0.18 0.06 360 -0.14
25/57 L I/P 7.06 2.09 - 0.02 -0.06 -165 -1.09
26/56 M I/C 5.92 2.76 0.08 0.05 -120 -1.58
27/50 L 1/ 10.84 3.36 -0.06 -0.04 -0,30
28/42 L A / 7.60 2.51 0.20 0.17 0.45
29/63* L IA/C 6.57 2.09 -1.27
30/49 M /CP 8.30 4.29 0.00 0.03 -1.50
31/52 M 1/ 7.60 4.14 - 0.01 0.02 60 0.22
32/54 L I/C 6.28 2.10 0.10 0.09 —240 -1.51
33/42 L / 7.03 2.00 -0.14 - 0.11 -0.50
34/56 M A,A/C 6,68 3.26 -0.06 -0.08 0 0.59
35/56 L A/C 6.66 2.03 - 0.11 -0.13 -55 -1.34
36/46 L / 8.84 4,02 0.00 0,03 -67 -0.36
37/49 M m i 7.31 4.48 0.07 - 0.01
38/50 M A/CP 5.83 2.79 0.24
39/62 L I/PC 6,36 2.59 -0,03 0.03 -60 -1,37
40/54 L If 6.38 2.27 0.03 - 0.01 -88 0.57
41/66 M Al 7,16 3.16 - 0.02 -0.07 -60
42/42 M I/P 13.90 9.29 0.20 0,15 5 -0.03
•Patient underwent repeat coronary artery bypass graft surgery (C) 12 weeks after start of low density lipoprotein (LDL) a phoresis and died postoperative^ due 
to low cardiac output. A = anterior myocardial infarction; Base = baseline; During = mean LDL cholesterol level during trial (for LDL aphercsis group [L|, data are 
time-averaged values [for conversion to mg/dl, multiply by 38.7]); I = inferior myocardial infarction; M -  medication; NO = non-Q wave myocardial infarction; P = 
percutaneous transluminal coronary angioplasty; Pt -  patient; AHMMT -  change in hyperemic mean transit time; AMOD = change in minimal obstruction diameter 
(baseline vs. follow-up); AMSD = change in mean segment diameter from quantitative coronaiy angioplasty measurements (baseline vs. follow-up); AST Time = 
change in time to i~mm (0.1 mV) ST segment depression.
the first study and subsequent follow-up were available. Paired 
data were missing in seven patients because of 1) insufficient 
image quality from one session in two patients and from both 
sessions in a third patient with chronic airway obstruction; 2) 
loss of stored digital images from one session in two patients; 
and 3) no comparable DSA in two patients.
Evaluation of myocardial perfusion based on individual 
ROIs. In total, 121 comparative ROIs were available, 68 in the 
LDL apheresis group and 53 in the medication group (mean 
3.5 ± 1.7/patient). One hundred three ROIs were generated in 
regions supplied by native coronary arteries and 18 supplied by 
bypass grafts. On the basis of the ROIs, the average HMTT
JA CC Vol. 28, No. 7
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Table 2. Regional Hyperemic Mean Transit Time Values in the 
Three Myocardial Perfusion Areas 0,45 ± 0.03 liter/liter, respectively, in the medication group
LAD
Region
LCx
Region
RCA
Region
All
Regions
LDL apheresis group n = 17 n = 18 n =  7 n = 42
Baseline HM TT (s) 3.28 (0.97) 2.93 (0.66) 4.61 (1.85) 3.35(1.18)
Follow-up HMTT (s) 2.81 (0.86) 2.66 (0.67) 3.57 (0.79) 2.87 (0.82)
p value 0.02 0.08 0 . 1 1 0 . 0 0 1
M edica tion  group n := 15 n = 13 n =  7 n = 35
Baseline HM TT (s) 2.78 (0.78) 3.15(1.22) 2.95 (1.35) 2.95 (1.06)
Follow-up HMTT (s) 2.75 (0.81) 3.11(1.07) 3.14 (0.79) 2.96 (0.90)
p value 0.88 0.93 0.74 0.96
D ifference  (p value)* 0.17 0.51 0.14 0.04
* Difference in mean change between low density lipoprotein apheresis and 
m ed ica tio n  group (t test). Data presented are mean value (SD). HMTT = 
hyperem ic  m ean transit time; LAD = left anterior descending coronaiy artery; 
L C x  =  left circumflex coronaiy artery; RCA ~ right coronaiy artery.
decreased by 0.59 ± 1.01 s in the LDL apheresis group (p < 
0.0001) and by 0.10 ± 1.16 s (p = 0.52) in the medication group 
(0.48-s between-group difference, p = 0.01).
Evaluation of regional myocardial perfusion (Table 2), Base­
l in e  HM TT values for the LDL apheresis and medication 
g roups  were 3.35 ± 1.18 s (n = 42) and 2.95 ± 1.06 s (n = 35), 
respectively, and were statistically not different (p = 0.52), The 
relative changes in HMTT in the three perfusion areas of the 
L A D , LCx and RCA are shown in Figure 3. All three coronaiy 
perfusion areas in the LDL apheresis group contributed 
equally to the final result.
Patient-based analysis. In the patient-based analysis the 
average HMTT value in the LDL apheresis group (n = 18) was 
3.19 ±  0.78 s at baseline and 2,74 ± 0.68 s at follow-up (mean 
difference —0.45 s [-14%], p = 0.01). In the medication group 
(n =  17), the average HMTT value was 2.99 ± 0.84 s at 
baseline and 2.94 ± 0.77 s at follow-up (mean difference 
—0.05 s [-2% ], p = 0.85), for a mean difference in change 
between the two groups of 0.40 s (p -  0.19).
Hematocrit measured at cardiac catheterization in the LDL 
apheresis group was 0.44 ± 0.03 at baseline and 0.43 ± 
0.04 liter/liter at follow-up (p = 0.23) and 0.45 ± 0.03 and
Figure 3. Bar graphs showing mean percent change in HMTT ± SEM 
in the regions of the LAD, LCx (ramus circumflexus [RCX]) and RCA, 
respectively, for the LDL apheresis group versus the medication group.
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(P 0.44). For correction of possible changes in blood
viscosity due to changes in hematocrit, the mean patient-based 
HMTT at follow-up catheterization was corrected by the 
percent change in hematocrit from baseline to follow-up 
catheterization. In the LDL apheresis group (n = 18), the 
average HMTT corrected for hematocrit change decreased 
from 3.19 ± 0.78 s at baseline to 2,78 ± 0.69 s at follow-up (p =
0.008) and from 2.99 ± 0.84 s at baseline to 2.97 ± 0.84 s at 
follow-up in the medication group (p = 0.94). The mean 
difference in HMTT between the LDL apheresis group and the 
medication group after correction for hematocrit was 0.38 s 
(p = 0.22), rather than 0.40 s without correction for hematocrit 
changes.
There were no significant correlations between the change 
in percent as well as absolute changes in HMTT with the mean 
lipid levels during the trial [total cholesterol, LDL cholesterol, 
high density lipoprotein cholesterol, ratio of LDL to high 
density lipoprotein cholesterol, lipoprotein(a)] or relative and 
absolute changes in lipid levels. No significant correlations 
were found between percent changes as well as absolute 
changes in HMTT and minimal obstruction diameter, mean 
segment diameter and time to 1-mm ST segment depression. 
Classification of the patients into two groups (improvement vs. 
no change in or impairment of time to 1-mm ST segment 
depression at exercise test) showed a decrease in HMTT of 
16 ± 21% in the group with improvement versus an increase in 
HMTT of 4 ± 19% in the group with no change or impairment 
(p = 0.04). The change in hematocrit at cardiac catheterization 
was not related to the time to 1-mm ST segment depression or 
to the change in HMTT.
Discussion
Although the LAARS trial showed no significant change in 
quantitatively assessed coronary anatomy in both groups, the 
results of the HMTT measurements showed an increase in 
myocardial perfusion in the LDL apheresis group, whereas the 
medication-only group remained in stable condition. This 
improvement in myocardial perfusion in the LDL apheresis 
group is in agreement with the improved ischemic threshold 
that has been previously reported (11,36). These results show 
a discrepancy between anatomic and physiologic variables in 
the assessment of coronary atherosclerosis. The improved 
functional status in the LDL apheresis group was accompanied 
by a lower LDL cholesterol level (1.1 mmol/liter) than in the 
medication-only group. To explain the improvement in myo­
cardial perfusion, we hypothesized that one or more of the 
following mechanisms may be operative:
1. Recovery of endothelial nitric oxide production and release 
in the conduit vessels. Recent studies in animals and humans 
(21-25,37) associate hypercholesterolemia and increased 
Lp(a) levels with impaired endothelium-dependent vasodila­
tion. Lipid lowering during 6 months to 1 year may enhance 
endothelial function, as assessed with acetylcholine (27-29). 
improvement in endothelial function may enhance exercise-
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induced dilation of the large epicardial coronary arteries 
(21,38). Short-term cholesterol lowering with LDL apheresis 
directly improves endothelium-dependent relaxation of the 
epicardial coronary arteries, suggesting a direct effect of LDL 
cholesterol (39). The more pronounced lipid lowering in the 
LDL apheresis group in this study may result in better recovery 
of endothelial function and may thus improve the ischemic 
threshold at exercise testing. Assessment of HMTT reveals a 
time variable that is inversely related to maximal myocardial 
perfusion. Because of the method of assessment of HMTT 
(intracoronary papaverine and sublingual isosorbide dinitrate), 
it is unlikely that endothelium-dependent vasodilation is in­
volved in the improved regional myocardial perfusion observed 
in this study.
2, Remodeling of the conduit vessel wall Progression or 
regression of coronaiy arteiy stenosis may be associated with 
complex shape changes or remodeling (40), in which the 
integrated hemodynamic effects on the coronary circulation 
may differ from the changes in minimal obstruction diameter 
and mean segment diameter. According to Glagov et al. (41) 
and Stiel et al. (42), progression of coronary artery disease 
leads initially to compensatory dilation. In the setting of 
regression of atherosclerotic plaques, this process might be 
reversed, with remodeling of the vessel wall without a signifi­
cant effect on lumen cross-sectional area of the epicardial 
coronary arteries. However, the dilation of the remodeled 
coronary arteries in response to papaverine may be enhanced, 
and maximal myocardial perfusion may be increased. This view 
is supported by a recent publication (43) in which the epicar­
dial response to intracoronary nitroglycerin administration 
decreased significantly with increasing atherosclerotic wall 
thickening. Next to obstruction of the vascular lumen, athero­
sclerosis of the arterial wall also has an endothelium- 
independent effect on coronary vasomotion and flow. Decrease 
in atherosclerotic thickening of the arterial wall without a 
direct effect on the lumen size of the vessel may explain the 
observation that functional improvement precedes anatomic 
regression of atherosclerosis.
3. Improved arteriolar vasodilation. Resistance vessels are 
spared from the development of overt atherosclerosis. How­
ever, relaxation of these vessels may be reduced in patients 
with high LDL cholesterol levels due to alterations in endo­
thelial cell function, as established in primates (23). 
Endothelium-dependent arteriolar relaxation was impaired, 
whereas endothelium-independent responses were nearly 
identical (23). In the human forearm model, the impairment of 
microvascular vasodilator function in patients with hypercho­
lesterolemia is endothelium-dependent only (25); thus, im­
provement in endothelium-independent arteriolar vasodilation 
as a mechanism for our results is highly speculative. Another 
hypothesis, introduced by Gould et al. (44), is that the coronary 
flow response induced by direct effect of an arteriolar vasodi­
lator may be augmented by further improvement in flow- 
mediated, endothelium-dependent epicardial coronary artery 
vasodilation. However, this effect was not likely to occur in this 
study, where patients received isosorbide dinitrate for epicar-
diai coronary artery vasodilation before angiography. Maximal 
epicardial vasodilation after sublingual isosorbide dinitrate is 
known (45,46) to persist for 30 to 60 min, which was the time 
needed in this study to perform angiography and DSA.
4. Changes in blood rheology. Improved myocardial perfu­
sion might be due to changes in blood rheology as a result of 
repeated LDL apheresis (47,48). Because of this observation, 
assessment of HMTT in the present study was performed 1 
month after final LDL apheresis to avoid a direct effect of LDL 
apheresis on viscosity. In LDL apheresis over dextran sulfate 
cellulose columns, plasma fibrinogen, a determinant of viscos­
ity, is lowered acutely by 26% to 35%, returning to pretreat­
ment levels between 2 and 7 days (11,49). Seven days after 
LDL apheresis plasma viscosity is unchanged, but blood vis­
cosity is still reduced, independent of the change in hematocrit 
(48). Rigidity of red blood cells is increased in patients with 
high LDL cholesterol values, causing elevated blood viscosity. 
Low density lipoprotein apheresis improves the erythrocyte 
deformability, but how long this effect lasts after multiple 
procedures is unknown. In the study of Rubba et al. (48), 3 
weeks after the last of six procedures for LDL apheresis, peak 
blood flow in the leg was significantly increased, whereas that 
in the forearm was unchanged. During our study, there was a 
small decrease in hematocrit in the LDL apheresis group, but 
at cardiac catheterization the hematocrit levels were not 
significantly different within and between both groups. The 
results of HMTT analysis after correction for change in 
hematocrit were virtually unchanged; we therefore decided to 
use the original data set for the entire analysis.
In our opinion, two of the four potential mechanisms are 
the most attractive explanations for the improved myocardial 
perfusion in the LDL apheresis group. 1) The concept of the 
remodeling of the vessel wall. It is conceivable that although 
lumen dimensions have not (yet) changed significantly, the 
total atherosclerotic burden of the vessel wall has decreased 
(“reversed Glagov sequence”), conditioning the vessel wall for 
an increased response to a muscle relaxant such as papaverine. 
In our study, lumen dimensions were assessed after adminis­
tration of isosorbide dinitrate but without papaverine, whereas 
HMTT measurements were performed both after isosorbide 
dinitrate and papaverine. 2) The improved rheologic condition 
caused by LDL apheresis. The circumstantial evidence that 
viscosity remained unchanged between baseline and follow-up 
catheterization because of unchanged hematocrit and un­
changed fibrinogen might be insufficient. Whole-blood viscos­
ity is determined by many other factors, such as erythrocyte 
deformability and triglyceride and total cholesterol levels. 
Decreased whole-blood viscosity might have contributed to the 
improved maximal myocardial perfusion.
Further lipid-lowering studies should use intracoronary 
echocardiography to evaluate the total atherosclerotic burden 
and the existence of a “reversed Glagov sequence,” combined 
with analysis of the vascular reaction to papaverine. Further­
more, analysis of whole-blood viscosity is needed to under­
stand the basic interactions between lipid-lowering, viscosity,
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endothelium-dependent and endothelium-independent vascu­
lar responses and myocardial perfusion.
Limitations of the study. The HMTT is inversely related to 
flow if the vascular volume remains constant: t = V/F, where 
t =  mean transit time; F = flow; and V -  vascular volume 
between the site of injection and point of measurement. 
Assessment of HMTT was based on the assumption that 
vascular volume after intracoronary papaverine administration 
w as maximal and equal at baseline and follow-up cardiac 
catheterization. Theoretically, if vascular volume were smaller 
because of atherosclerosis and flow remained the same, a 
sh o rte r  mean transit time could also be found that erroneously 
cou ld  be interpreted as favorable. This type of error is very 
unlikely because vascular volume is mainly determined by 
arterioles and capillaries, vessels that are not involved in the 
atherosclerotic process. In addition, the unchanged mean 
segm ent diameter in this study supports the assumption that 
th e  vascular volume of the conduit vessels remained un­
changed.
In  this study, regional myocardial perfusion was assessed as 
th e  primary end point for flow evaluation. For patient-based 
H M T T  values, regions from one patient were averaged to one 
H M T T  value. However, in some patients only one region was 
available; in one patient even based on only one ROI. In the 
o th e r  patients, eight ROIs in three myocardial perfusion areas 
w e re  available (including bypass evaluation). Therefore, 
patient-based HMTT values are not always representative of 
th e  entire myocardial perfusion in that patient.
Conclusions. Biweekly LDL apheresis plus simvastatin im­
proved regional myocardial perfusion in patients with severe 
hypercholesterolemia and extensive coronaiy artery disease, In 
the  control group, treated with lipid-lowering drugs only, 
regional myocardial perfusion remained stable. The improve­
m en t in myocardial perfusion is in agreement with that in 
ischemic threshold at exercise testing. The additional decrease 
in LDL cholesterol levels from LDL apheresis may be one 
explanation for the functional improvement in coronary circu­
lation, although rheologic changes cannot be ruled out. Func­
tional improvement may be due to endothelium-dependent or 
endothelium-independent changes, or both, in the coronaiy 
circulation. Further studies will be needed for elucidation of 
the  exact mechanism. Calculation of the regional myocardial 
perfusion by DSA with videodensitometric calculation of the 
H M T T  is feasible for evaluation of lipid-lowering trials, This 
method requires some minor modifications of the radiographic 
equipment and intensive instructions for the patient for breath 
holding. Assessment of regional myocardial perfusion in lipid- 
lowering studies has the benefit of combined evaluation of the 
epicardial coronary tree as well as the microcirculation.
Wc thank D. Kampschreur and the nursing staff of the cardiac catheterization 
unit for their excellent assistance during cardiac catheterization and T, Pijnen­
burg for help with the processing and analysis of the DSA studies.
References
1. Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary 
heart disease in familial hypercholesterolemia. Circulation 1989;79:225-32,
2. Tatami R, Inoue N, Itoh H, et al., for the LARS Investigators. Regression of 
coronary atherosclerosis by combined LDL-apheresis and lipid-lowering 
drug therapy in patients with familial hypercholesterolemia: a multicenter 
study. Atherosclerosis 1992;95:1-13.
3. Gordon BR, Kelsey SF, Bilheimer DWr et al,, for the Liposorber Study 
Group. Treatment of refractory familial hypercholesterolemia by low-density 
lipoprotein apheresis using an automated dcxtran sulfate cellulose adsorp­
tion system. Am J Cardiol 1992;70:1010-6.
4. Gordon BR, Stein E, Jones, P, Illingworth DR. Indications for low-density 
lipoprotein apheresis. Am J Cardiol 1994;74:1109-12.
5. Hombach V, Borberg H, Gadzkowski A, Oette K, StofFel W. Regression der 
Koronarsklerose bei familiarer Hypercholesterinamie IIa durch spezifische 
LDL'Apherese, Dtsch Med Wochenschr 1986;11:1709-15.
6 . Yamamoto A, Regression of atherosclerosis in humans by lowering serum 
cholesterol, Atherosclerosis 1991;89:1-10.
7. Kitabatake A, Sato H, Hori M, et al, for the Osaka LDL-Apheresis 
Multicenter Trial Group. Coronaiy atherosclerosis reduced in patients with 
familial hypercholesterolemia after intensive cholesterol lowering with low- 
density-lipoprotein-apheresis; 1-ycar follow-up study. Clin Ther 1994; 16: 
416-28.
8 . Schuff-Werner P, Gohlke H, Bartmann U, et al., and the HELP-Study 
Group. The HELP-LDL-apheresis multicentre study, an angiographically 
assessed trial on the role of LDL-apheresis in the secondary prevention of 
coronaiy heart disease. II. Final evaluation of the effect of regular treatment 
on LDL-cholesterol plasma concentrations and the course of coronaiy heart 
disease, Eur J Clin Invest 1994;24:724-32.
9* Thompson GR, Miller JP, Breslow JL. Improved survival of patients with 
homozygous familial hypercholesterolemia treated by plasma exchange. 
BMJ 1985;291:1671-3.
10. Thompson GR, Maher WMG, Matthews S, et al, Familial Hypercholester­
olemia Regression Study; a randomised trial of low-density-lipoprotein 
apheresis, Lancet 1995;345:811-6.
11. Kroon A A, Aengevaeren WRM, van der Werf T, et a t The LDL-Apheresis 
Atherosclerosis Regression Study (LAARS): effect of agressive versus 
conventional lipid lowering treatment on coronaiy atherosclerosis. Circula­
tion 1996;93:1826-35.
12. The Scandinavian Simvastatin Survival Study Group. Randomised trial of 
cholesterol lowering in 4444 patients with coronaiy heart disease: the 
Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:383-9,
13. Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary 
Prevention Study Group. Prevention of coronary heart disease in men with 
hypercholesterolemia. N Engl J Med 1995;333:1301-7.
14. Brown G, Albers JJ, Fisher LD, et al. Regression of coronaiy artery disease 
as a result of intensive lipid-lowering therapy in men with high levels of 
apolipoprotein B, N Engl J Med 1990;323:1289-98.
15. Jukema JW, Bruschke AVG, van Boven AJ, et al., on behalf of the 
REGRESS Study Group. Effects of lipid lowering by pravastatin on progres­
sion and regression of coronary artery disease in symptomatic men with 
normal to moderately elevated serum cholesterol levels: the “Regression 
Growth Evaluation Stalin Study” (REGRESS). Circulation 1995;91:2528-
40.
16. de Feyter PJ, Serruys PW, Davies MJ, Richardson P, Lubsen J, Oliver MF. 
Quantitative coronaiy angiography to measure progression and regression of 
coronaiy atherosclerosis: value, limitations, and implications for clinical 
trials. Circulation 1991;84:412-23.
17. Gibson CM, Sandor T, Stone PH, Pasternak RC, Rosner B, Sacks FM. 
Quantitative angiographic and statistical methods to assess serial changes in 
coronary luminal diameter and implications for atherosclerosis regression 
trials. Am J Cardiol 1992;69:1286-90.
18. Hong MK, Mintz GS, Popma JJ, et al. Limitations of angiography for 
analyzing coronary atherosclerosis progression or regression Ann Intern 
Med 1994;121:348-54.
19. Topol EJ, Nissen SE. Our preoccupation with coronaiy luminology: the 
dissociation between clinical and angiographic findings in ischemic heart 
disease. Circulation 1995;92:2333-42.
20. Brown BG> Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque
1704 AENGEVAEREN ET AL.
LDL APHERESIS IMPROVES REGIONAL MYOCARDIAL PERFUSION
JACC Vol. 28, No. 7
December 1996:1696-704
regression; new insights into prevention of plaque disruption and clinical 
events in coronary disease. Circulation 1993;87:1781-91.
21. Cox DA, Vita JA, Treasure CB, et al. Atherosclerosis impairs flow-mediated 
dilatation of coronaiy arteries in humans. Circulation 1989;80:458-65.
22. Liiseher TF, Richard V, Tschudi M, Yang Z, Boulanger C. Endothelial 
control of vascular tone in large and small coronary arteries. J Am Coll 
Cardiol 1990;15:519-27.
23. Selike FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular 
relaxation is abnormal in the coronaiy microcirculation of atherosclerotic 
primates. Circulation 1990;81:1586-93.
24. Zeihcr AM, Drcxler H, Sauerbier B, Just H. Effects of age, atherosclerosis, 
hypercholesterolemia, and hypertension: endothelium-mediated coronary 
flow modulation in humans. J Clin Invest 1993;92:652-62.
25. GiJligan DM, Guetta V, Panza JA, García CE, Quyyumi AA, Cannon RO. 
Selective loss of microvascular endothelial function in human hypercholes­
terolemia. Circulation 1994;90:35-41.
26. Cclermajer DS, Sorensen ICE, Gooch VM, et al, Non-invasive detection of 
endothelial dysfunction in children and adults at risk of atherosclerosis, 
Lancet 1992;340:1111-5.
27. Egashira K, Hirooka Y, Kat H, et al. Reduction of serum cholesterol with 
pravastatin improves endothelium-dependent coronary vasomotion in pa­
tients with hypercholesterolemia. Circulation 1994;89:2519-24.
28. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of 
cholesterol-lowering therapy on the coronaiy endothelium in patients with 
coronary artery disease. N Eng! J Med 1995;332:481-7.
29. Anderson TJ, Meredith IT, Yeung AG, Frei B, Selwyn AP, Ganz P, The 
effect of cholesterol-lowering and antioxidant therapy on endothelium- 
dependent coronaiy vasomotion. N Engl J Med 1995;332:488-93.
30. Benzuly KH, Padgett RC, Kaul S, Piegors DJ, Armstrong ML, Heistad DD. 
Functional improvement precedes structural regression of atherosclerosis. 
Circulation 1994;89:1810-8.
31. Werf T van der, Heethaar RM, Stegehuis H, Meijler FL. The concept of 
apparent cardiac arrest as a prerequisite for coronary digital subtraction 
angiography. J Am Coll Cardiol 1984;4:239-44.
32. Pijls NHJ, Uijen GJH, Hoevelaken A, et al. Mean transit time for assessment 
of myocardial perfusion by videodensitometry. Circulation 1990;81:1331-40.
33. Pijls NHJ, Uijen GJH, Pijnenburg T, et al. Reproducibility of the mean 
transit time for maximal myocardial flow assessment by videodensitometry. 
Intern J Cardiac Imaging 1991;6:101-8,
34. Pijls NHJ, Aengevaeren WRM, Uijen GJH» et al. Concept of maximal flow 
ratio for immediate evaluation of percutaneous transluminal coronary 
angioplasty result by videodensitometry. Circulation 1991;83:854-65.
35. Wells R. Syndromes of hyperviscosity. N Engl J Med 1970;283;183-6,
36. Tait GW, Packard CJ, Shepherd J, Hutton I, Lorimer RA, Cholesterol 
reduction and regression of coronary atherosclerosis: the Coronary Ather­
oma Regression Study. In: Gordon BR, Gotto AM, editors. The Treatment
of Severe Hypercholesterolemia: Can We Impact Disease Course? Princeton 
(NJ): Exerpta Medica, 1992:80-9.
37. Tsurumi Y, Nagashima H, Ichikawa KI, Sumiyoshi T, Hosoda S. Influence of 
plasma lipoprotein(a) levels on coronary vasomotor response to acetylcho­
line. J Am Coll Cardiol 1995;26:1242-50.
38. Berdeaux A, Ghaleli B, Dubois-Rande JL, et al. Role of vascular endothe­
lium in exercise-induced dilation of large epicardial coronary arteries in 
conscious dogs. Circulation 1994;89:2799-808.
39. Jgarasbi K, Horimoto M, Takenaka T, Inoue H, Miyata S. Acute cholesterol 
lowering with LDL-apheresis improves endothelial function of the epicardial 
coronary artery in patients with hypercholesterolemia [abstract]. J Am Coll 
Cardiol 1996;27:19A.
40. Gould KL, Ornisch D, Kirkeeidie R, et al. Improved stenosis geometry by 
quantitative coronaiy arteriography after vigorous risk factor modification. 
Am J Cardiol 1992;69:845-53.
41. Glagov S, Weisenberg E, Zarins DK, Stankunavicus R, Kolettis BA. 
Compensatory enlargement of human atherosclerotic coronary arteries.
N Engl J Med 1987;316:1371-5.
42. Stiel GM, Sticl LSG, Schofer J, Donath K, Mathey DDG. Impact of 
compensatory enlargement of atherosclerotic coronaiy arteries on angio­
graphic assessment of coronaiy artery disease. Circulation 1989;80:1603-9.
43. Schachinger V, Zeiher AM. Quantitative assessment of coronaiy vasoreac- 
tivity in humans in vivo: importance of baseline vasomotor tone in athero­
sclerosis. Circulation 1995;92:2087-94.
44. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering 
decreases size and severity of perfusion abnormalities by positron emission 
tomography after dipyridamole in patients with coronary arteiy disease: a 
potential noninvasivc marker of healing coronaiy endothelium. Circulation 
1994;89:1530-8.
45. Badger RS, Brown BG, Gallery CA, Bolson EL, Dodge HT. Coronary artery 
dilation and hemodynamic responses after isosorbide dinitrate therapy in 
patients with coronary artery disease. Am J Cardiol 1985;56:390-5.
46. Jost S, Rafflenbeul W, Reil GH, et al. Reproducible uniform coronary 
vasomotor tone with nitrocompounds: prerequisite of quantitative coronary 
angiographic trials. Cathet Cardiovasc Diagn 1990;20:168-73,
47. Schuff-Werner P, Schütz E, Seyde WC> et al. Improved hacmorrheology 
associated with a reduction in plasma fibrinogen and LDL in patients being 
treated by heparin-induced extracorporeal LDL precipitation, Eur J Clin 
Invest 1989;19:30-7.
48. Rubba P, Iannuzzi A, Postiglione A, et al. Hemodynamic changes in tlie 
peripheral circulation after repeat low density lipoprotein apheresis in 
familial hypercholesterolemia. Circulation 1990;81:610-6.
49. Knisel W, Di Nicuolo A, Pfohl M, et al. Different effects of two methods of 
low-density lipoprotein apheresis on the coagulation and fibrinolytic system.
J Intern Med 1993;234:479-87.
